Fingerprint
Dive into the research topics of 'The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Kenneth R. Chapman, Frank C. Albers, Bradley Chipps, Xavier Muñoz, Gilles Devouassoux, Miguel Bergna, Dmitry Galkin, Jay Azmi, Dalal Mouneimne, Robert G. Price, Mark C. Liu
Research output: Contribution to journal › Article › peer-review
42
Scopus
citations